Mantle cell lymphoma: observation to transplantation

Sweetenham, John W.

doi:10.1177/2040620714561579

Cited by 20 publications

(13 citation statements)

References 84 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While R-CHOP is commonly used in certain clinical situations, its use as initial treatment without subsequent consolidation with ASCT or maintenance rituximab has lost favor [Rajabi and Sweetenham, 2015]. A retrospective review conducted by LaCasce and colleagues showed R-CHOP resulted in inferior outcomes than the more intense R-HyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytarabine) regimen, regardless of the use of consolidation with ASCT.…”

Section: Treatment Approaches To MCLmentioning

confidence: 99%

Bortezomib for the treatment of mantle cell lymphoma: an update

Hambley

Caimi

William

2016

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Bortezomib is a first in class proteasome inhibitor, initially approved by the US Food and Drug Administration for the treatment of plasma cell myeloma. Bortezomib has been approved for the treatment of relapsed and refractory mantle cell lymphoma (MCL) and, more recently, in the upfront setting as well. Treatment algorithms for MCL have rapidly evolved over the past two decades, and the optimal regimen remains to be defined. The choice of treatment regimen is based on disease risk stratification models, the expected toxicity of antineoplastic agents, the perceived patient ability to tolerate the planned treatments and the availability of novel agents. As new drugs with novel mechanisms of action and variable toxicity profiles come into use, treatment decisions for a given patient have become increasingly complex. This article provides an overview of the evolving use of bortezomib in the rapidly changing management landscape of MCL.

show abstract

Section: Treatment Approaches To MCLmentioning

confidence: 99%

Bortezomib for the treatment of mantle cell lymphoma: an update

Hambley

Caimi

William

2016

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

show abstract

“…At present, various treatments are used for MCL: Chemotherapy; bone marrow transplantation; radiotherapy; immunotherapy; and targeted therapy. However, to date, no consensus regarding the optimal treatment has been reached among physicians, and rapid relapses hamper their curative effect (19). As a result, MCL has a relatively short median survival time of 5–7 years (20–22).…”

Section: Introductionmentioning

confidence: 99%

Exosome complex genes mediate RNA degradation and predict survival in mantle cell lymphoma

Zhang

Zhu

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Exosome complex (EXOSC) genes, which encode a multi-protein intracellular complex, mediate the degradation of various types of RNA molecules. EXOSCs, also known as polymyositis/scleroderma complexes, exist in eukaryotic cells and archaea, and primarily mediate 3′ to 5′mRNA degradation. However, how EXOSC genes are implicated in processes of B-cell immune-associated pathways and B-cell tumorigenesis remains unclear. The present bioinformatics study indicated that 6 of 10 EXOSC genes, particularly the EXO.index, were able to predict the survival of patients with mantle cell lymphoma (MCL), by analyzing gene expression profiles of 123 patients with MCL from the Gene Expression Omnibus database. The results suggested that EXOSC gene expression may be a molecular marker for MCL. Compared with the whole transcript profile, patients with MCL with a high EXO.index exhibited poorer survival and decreased RNA levels, which was also verified in a second dataset. The EXOSC genes may be associated with DNA repair and B-cell activation pathways, which may be the cause of poorer survival of patients with MCL.

show abstract

“…Mantle cell lymphoma (MCL) is an aggressive subtype of NHL and is generally considered incurable, even despite intensive therapeutic approaches. 23 It is characterized by the t(11:14) chromosomal translocation which results in dysregulation and overexpression of the cell cycle protein cyclin D1. 24 MCL accounts for~5-10% of NHL cases and has been increasing in incidence in the past two decades.…”

Section: Mantle Cell Lymphomamentioning

confidence: 99%

Post-autologous transplant maintenance therapies in lymphoma: current state and future directions

Riedell

Bishop

2017

Bone Marrow Transplant

View full text Add to dashboard Cite

Disease relapse following high-dose chemotherapy and autologous stem cell transplant (ASCT) remains the principal cause of mortality in patients with relapsed or refractory lymphomas. In an effort to prevent post-ASCT relapse, a number of studies have evaluated the role of maintenance therapy with varying success. In diffuse large B-cell lymphoma, studies evaluating maintenance rituximab (MR) following ASCT failed to demonstrate improved outcomes. In follicular lymphoma, MR was associated with an improvement in PFS; however, no overall survival (OS) benefit was noted. Emerging data evaluating MR in mantle cell lymphoma (MCL) have demonstrated improvements in PFS, although a consistent improvement in OS has yet to be demonstrated. Given the aggressive and incurable nature of MCL, it is prudent for practitioners to weigh the risks and benefits of MR in the post-ASCT setting. Similarly, post-ASCT maintenance therapy with brentuximab vedotin in Hodgkin lymphoma, has led to improved PFS and may be considered in those with a high risk of relapse. Ongoing clinical studies evaluating a multitude of novel maintenance therapies are crucial to the efforts of further defining and optimizing the role of post-transplant maintenance therapy in lymphoma.

show abstract

Mantle cell lymphoma: observation to transplantation

Cited by 20 publications

References 84 publications

Bortezomib for the treatment of mantle cell lymphoma: an update

Bortezomib for the treatment of mantle cell lymphoma: an update

Exosome complex genes mediate RNA degradation and predict survival in mantle cell lymphoma

Post-autologous transplant maintenance therapies in lymphoma: current state and future directions

Contact Info

Product

Resources

About